Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Pharma
Amgen, AZ's Tezspire lands ph. 3 eosinophilic esophagitis win
The eosinophilic esophagitis trial win positions the anti-TSLP biologic to potentially expand into its third inflammatory disease indication.
Angus Liu
Aug 27, 2026 10:17am
FDA rejection letters flag data concerns for AZ, GSK biologics
Mar 3, 2026 11:30am
Upside for Insmed after Brinsupri’s first-in-class sales beat
Jan 9, 2026 10:40am
GSK scoops up yet another FDA approval, this time in asthma
Dec 17, 2025 8:30am
GSK's long-acting asthma med wins CHMP backing
Dec 12, 2025 11:27am
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Jul 29, 2025 8:50am
